At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
SYD985drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy
In Brief
A Phase 2 clinical trial evaluating SYD985 for Endometrial Cancer. Completed, enrolled 64 participants across 36 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of SYD985 in recurrent, advanced or metastatic endometrial cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Cancer
CountriesPoland, Russia, Serbia, Singapore, South Korea, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartMay 2020
Primary CompletionJan 2023
Study CompletionApr 2023
TodayJul 2026
First PostedDec 19, 2019
Enrollment StartMay 28, 2020
Primary CompletionJan 26, 2023
Study CompletionApr 25, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.5 years ago
Interventions
SYD985drug
SYD985 powder for concentrate for solution for infusion